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Accumulation of atherosclerotic plaque in the wall of our
coronary arteries is often described as ubiquitous, unavoid-
able, and innocent, except for instances where it might cause
either obstructive or eruptive disease. Obstructive athero-
sclerotic disease occurs when excess plaque accumulates
beyond maladaptive positive remodeling. Then luminal
encroachment might cause stress-induced ischemia. Erup-
tive atherosclerotic disease relates to plaque composition
and activity more than to stenosis severity and causes unstable
angina, myocardial infarction, or sudden cardiac death due to
atherothrombosis and abrupt coronary artery occlusion. It is
said that the former hurts, whereas the latter kills.
See pages 502 and 510
The evidence supporting these paradigms is restricted to
clinical pathological observations that were obtained in
patients having reached the tail end of the spectrum of
coronary artery disease (CAD). Because coronary athero-
sclerosis could only be detected during catheter-based pro-
cedures—be it by angiography, intravascular ultrasound,
optical coherence tomography, and few other invasive im-
aging techniques—limited information was available on the
significance of earlier stages of coronary atherosclerotic
disease in healthy carriers of the disease or subjects with
atypical or mild symptoms.
With the advent of coronary computed tomographic
angiography (CCTA), coronary anatomy and the progress
of atherosclerosis can be directly imaged non-invasively,
with the potential of revealing preclinical stages of the
disease. From this perspective, the current publication by
Lin et al. (1) represents an essential milestone contribution.
Lin et al. (1) have indeed studied and analyzed in detail by
CCTA the coronary anatomy of over 2,500 subjects;
follow-up was obtained for 3 years on average, and 58
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have CAD and had variable risk profiles and an 11%
estimated 10-year risk of CAD (by modified Framingham
risk score). Symptoms were variable but typical for angina in
1 of 3 subjects. The CCTA was able to rule out any CAD
involvement in nearly 60% of the subjects, who experienced
a very low rate of yearly mortality during follow-up (0.34%).
The presence of any plaque was associated, after adjusting
for risk factors, with 1.98 hazard ratio for all-cause mortal-
ity. With more extensive plaque burden, mortality risk
increased sharply up to 5.12 hazard ratio with 5 or more
coronary segments showing non-obstructive plaque. The
authors conclude that “the presence and extent of non-
obstructive plaque augments prediction of incident mortal-
ity above and beyond conventional clinical risk assessment.”
Importance of plaque composition. It is striking that Lin
et al. (1) could not identify any relationship between
intermediate-term mortality and plaque composition, de-
fined as noncalcified, calcified, or mixed. Kristensen et al.
(2) have revisited this issue in 312 patients presenting with
non–ST-segment elevation myocardial infarction (NSTEMI)
undergoing both CCTA and invasive angiography. Of
1.454 lesions detected by CCTA, 313 obstructive lesions
were revascularized and 1.141 deemed non-obstructive.
Per-patient revascularization rate was 75%. After a mean
follow-up of 16 months, 23 events occurred, of which only
4 were revascularization procedures. Predictive value of
CCTA-derived variables was assessed by univariate and
multivariate regression analysis. The no-obstructive, no-
calcified plaque volume provided incremental prognostic
value (hazard ratio: 1.18, 95% CI: 1.06 to 1.31, p  0.002)
over clinical variables, including multivessel disease, prior
myocardial infarction, and left ventricular ejection fraction.
High residual risk after NSTEMI was again identified by
increased nonobstructive plaque burden. Of note, from the
reported number of diseased vessels, invasive coronary
angiography had detected nearly 450 significant stenoses, of
which over 130 were left untreated. Because follow-up data
were obtained from electronic discharge letters, the new
culprit lesions in the event group could not be identified as
“non-obstructive” or “obstructive left untreated” at index
evaluation.
Nevertheless, both studies (1,2) suggest that the load of
nonobstructive plaque contributes to survival outcome,
across the spectrum of CAD, from mildly symptomatic
subjects to acutely sick patients.
Study limitations. Both groups of authors (1,2) provide a
lucid description of the limitations of their respective
studies, including the finite spatial resolution of 64-detector
row CCTA; the variability and limited accuracy of plaque
characterization; the lack of quantitative analysis of stenosis
severity; the absence of detailed evaluation of plaque
make-up with, for instance, intravascular ultrasound imag-
ing; and the absence of complementary evaluation with
calcium scoring. Lin et al. (1) caution against extrapolating
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jects who would undergo CCTA for screening purposes.
Kristensen et al. (2) acknowledge the relatively small sample
size of their study, the limited number of events, and the
lack of demonstration of a causal relationship between acute
events and nonobstructive plaque burden.
However, the main limitation of both studies was not
mentioned, namely that lone anatomic evaluation of steno-
sis severity does not qualify the physiological significance of
obstruction from the hemodynamic viewpoint. Both Meij-
boom et al. (3) and Sarno et al. (4) have shown that 7% to
12% of seemingly nonobstructive plaques are actually re-
sponsible for significantly decreased pressure-derived frac-
tional flow reserve. In addition, diffuse atherosclerosis with-
out focal luminal encroachment can also prevent matching
flow increases in response to demand, thereby causing
myocardial ischemia (5). The popular dichotomous para-
digm that opposes chronic, intermittent ischemia caused by
severe obstruction—on the one hand—with acute, unpre-
dictable ischemia caused by sudden disruption of non-
obstructive but active plaque—on the other—therefore
remains plausible but unproven. It can indeed be hypothe-
sized that coronary events will occur mostly in the subset of
patients carrying plaque that seems mild by anatomy but is
significant by hemodynamic status. Only prospective studies
combining noninvasive evaluation of coronary anatomy and
function will unravel whether chronic and acute presenta-
tions of CAD indeed stem from distinct mechanisms or
share a common substrate
Clinical implications. Notwithstanding putative mecha-
nisms, it remains that increasing non-obstructive plaque
burden identifies subjects at risk of dying in the intermedi-
ate term, beyond conventional risk factors and profiles.
Patients recovering from NSTEMI require extensive sec-
ondary prevention anyhow. Additional therapies (6) beyond
current standard of care, aiming at reducing the excess
residual risk, are currently being tested in the SOLID–
TIMI 52 (Stabilization Of pLaques usIng Darapladib–
Thrombolysis In Myocardial Infarction 52) and STABILITY
(Stabilization of Atherosclerotic Plaque by Initiation of
Darapladib Therapy) trials.
Lin et al. (1) are suggesting that mildly symptomatic
subjects who would not qualify for primary prevention
otherwise might benefit from lifestyle modification and drug
therapy, given the risk associated with nonobstructive
plaque burden on CCTA, with the potential of risk reduc-
tion and survival benefit. In their study, subjects without
plaque had 1.2% mortality over 3 years, as opposed to 3.4%in the presence of any nonobstructive plaque. Assuming a
realistic 10% relative risk reduction with treatment, at least
30,000 subjects/study arm should be included. To demon-
strate that such personalized intervention might be more
efficacious and/or cost-effective in the mid-term than pre-
ventative measures targeting the entire population as a
blanket strategy, subsets at even higher risk with a substan-
tial number of nonobstructive plaques (so-called triple-
vessel nonobstructive disease) should be included. Indeed, a
10% relative risk reduction from a control 10% mortality
rate could be detected in a 28,000-patient, large, random-
ized clinical trial (14,000/arm).
For the first time, the study by Lin et al. (1) raises the
question and might support the opportunity for testing
“interventional” primary prevention in healthy carriers of
extensive non-obstructive CAD, detected by CCTA at an
early clinical stage.
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